1、Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal
clindamycin plus dexamethasone versus classic oral therapy in
toxoplasmic retinochoroiditis: a prospective randomized clinical
trial[J]. Int Ophthalmol, 2013, 33(1): 39-46. DOI: 10.1007/s10792-
012-9634-1.Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal
clindamycin plus dexamethasone versus classic oral therapy in
toxoplasmic retinochoroiditis: a prospective randomized clinical
trial[J]. Int Ophthalmol, 2013, 33(1): 39-46. DOI: 10.1007/s10792-
012-9634-1.
2、Mart%C3%ADnez%20Castillo%20S%2C%20Gallego-Pinazo%20R%2C%20Franc%C3%A9s-Mu%C3%B1oz%20E%2C%20et%20al.%0AMacular%20toxoplasmosis%20and%20intravitreal%20clindamycin%3A%20an%20alternative%0Ato%20oral%20treatment%5BJ%5D.%20Arch%20Soc%20Esp%20Oftalmol%2C%202012%2C%2087(3)%3A%2093-95.%0ADOI%3A%2010.1016%2Fj.oftal.2011.09.005.Mart%C3%ADnez%20Castillo%20S%2C%20Gallego-Pinazo%20R%2C%20Franc%C3%A9s-Mu%C3%B1oz%20E%2C%20et%20al.%0AMacular%20toxoplasmosis%20and%20intravitreal%20clindamycin%3A%20an%20alternative%0Ato%20oral%20treatment%5BJ%5D.%20Arch%20Soc%20Esp%20Oftalmol%2C%202012%2C%2087(3)%3A%2093-95.%0ADOI%3A%2010.1016%2Fj.oftal.2011.09.005.
3、Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of
intravitreal clindamycin and dexamethasone versus
pyrimethamine, sulfadiazine, and prednisolone in treatment of
ocular toxoplasmosis[J]. Ophthalmology, 2011, 118(1): 134-141.
DOI: 10.1016/j.ophtha.2010.04.020.Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of
intravitreal clindamycin and dexamethasone versus
pyrimethamine, sulfadiazine, and prednisolone in treatment of
ocular toxoplasmosis[J]. Ophthalmology, 2011, 118(1): 134-141.
DOI: 10.1016/j.ophtha.2010.04.020.
4、Daien V, Papinaud L, Gillies MC, et al. Effectiveness and safety of an intracameral injection of cefuroxime for the prevention of
endophthalmitis after cataract surgery with or without
perioperative capsular rupture[J]. JAMA Ophthalmol, 2016,
134(7): 810-816. DOI: 10.1001/jamaophthalmol.2016.1351.Daien V, Papinaud L, Gillies MC, et al. Effectiveness and safety of an intracameral injection of cefuroxime for the prevention of
endophthalmitis after cataract surgery with or without
perioperative capsular rupture[J]. JAMA Ophthalmol, 2016,
134(7): 810-816. DOI: 10.1001/jamaophthalmol.2016.1351.
5、Balducci N, Savini G, Barboni P, et al. Hemorrhagic occlusive
retinal vasculitis after first eye cataract surgery without subsequent
second eye involvement[J]. Ophthalmic Surg Lasers Imaging
Retina, 2016, 47(8): 764-766. DOI: 10.3928/23258160-20160808-
10.Balducci N, Savini G, Barboni P, et al. Hemorrhagic occlusive
retinal vasculitis after first eye cataract surgery without subsequent
second eye involvement[J]. Ophthalmic Surg Lasers Imaging
Retina, 2016, 47(8): 764-766. DOI: 10.3928/23258160-20160808-
10.
6、Ehmann DS, Adam MK, Kasi SK, et al. Hemorrhagic occlusive
retinal vasculitis and nonhemorrhagic vasculitis after
uncomplicated cataract surgery with intracameral vancomycin[J].
Retin Cases Brief Rep, 2017, 11(Suppl 1): S155-S158. DOI: 10.1097/
ICB.0000000000000389.Ehmann DS, Adam MK, Kasi SK, et al. Hemorrhagic occlusive
retinal vasculitis and nonhemorrhagic vasculitis after
uncomplicated cataract surgery with intracameral vancomycin[J].
Retin Cases Brief Rep, 2017, 11(Suppl 1): S155-S158. DOI: 10.1097/
ICB.0000000000000389.
7、Lenci LT, Chin EK, Carter C, et al. Ischemic retinal vasculitis
associated with cataract surgery and intracameral vancomycin[J].
Case Rep Ophthalmol Med, 2015, 2015: 683194. DOI: 10.1155/
2015/683194.Lenci LT, Chin EK, Carter C, et al. Ischemic retinal vasculitis
associated with cataract surgery and intracameral vancomycin[J].
Case Rep Ophthalmol Med, 2015, 2015: 683194. DOI: 10.1155/
2015/683194.
8、Witkin AJ, Chang DF, Jumper JM, et al. Vancomycin-associated
hemorrhagic occlusive retinal vasculitis: clinical characteristics of
36 eyes[J]. Ophthalmology, 2017, 124(5): 583-595. DOI: 10.1016/j.
ophtha.2016.11.042.Witkin AJ, Chang DF, Jumper JM, et al. Vancomycin-associated
hemorrhagic occlusive retinal vasculitis: clinical characteristics of
36 eyes[J]. Ophthalmology, 2017, 124(5): 583-595. DOI: 10.1016/j.
ophtha.2016.11.042.
9、Braga-Mele R, Chang DF, Henderson BA, et al. Intracameral
antibiotics: Safety, efficacy, and preparation[J]. J Cataract Refract
Surg, 2014, 40(12): 2134-2142. DOI: 10.1016/j.jcrs.2014.10.010.Braga-Mele R, Chang DF, Henderson BA, et al. Intracameral
antibiotics: Safety, efficacy, and preparation[J]. J Cataract Refract
Surg, 2014, 40(12): 2134-2142. DOI: 10.1016/j.jcrs.2014.10.010.
10、中华医学会眼科学分会白内障及人工晶状体学组. 我国白内
障摘除手术后感染性眼内炎防治专家共识 (2017 年)[J]. 中华眼
科 杂 志 , 2017, 53(11): 810-813. DOI:10.3760/cma.j.issn.0412-
4081.2017.11.003.
Cataract and Artificial Lens Group of Ophthalmology Branch of
Chinese Medical Association. Expert consensus on prevention
and treatment of infectious intraocular inflammation after
cataract extraction surgery in China. Chin J Ophihalmol, 2017.
53(11): 810-813. DOI: 10.3760/cma.j.issn.0412-4081.2017.11.003.Cataract and Artificial Lens Group of Ophthalmology Branch of
Chinese Medical Association. Expert consensus on prevention
and treatment of infectious intraocular inflammation after
cataract extraction surgery in China. Chin J Ophihalmol, 2017.
53(11): 810-813. DOI: 10.3760/cma.j.issn.0412-4081.2017.11.003.
11、%E4%B8%AD%E5%8D%8E%E5%8C%BB%E5%AD%A6%E4%BC%9A%E7%9C%BC%E7%A7%91%E5%AD%A6%E5%88%86%E4%BC%9A%E7%9C%BC%E5%BA%95%E7%97%85%E5%AD%A6%E7%BB%84%2C%20%E4%B8%AD%E5%8D%8E%E5%8C%BB%E5%AD%A6%E4%BC%9A%E7%9C%BC%E7%A7%91%E5%AD%A6%E5%88%86%E4%BC%9A%0A%E7%99%BD%E5%86%85%E9%9A%9C%E5%8F%8A%E5%B1%88%E5%85%89%E6%89%8B%E6%9C%AF%E5%AD%A6%E7%BB%84%E4%B8%AD%E5%8D%8E%E5%8C%BB%E5%AD%A6%E4%BC%9A%E7%9C%BC%E7%A7%91%E5%AD%A6%E5%88%86%E4%BC%9A%E7%9C%BC%E5%A4%96%E4%BC%A4%E5%AD%A6%E7%BB%84%2C%20%E4%B8%AD%0A%E5%8D%8E%E5%8C%BB%E5%AD%A6%E4%BC%9A%E7%9C%BC%E7%A7%91%E5%AD%A6%E5%88%86%E4%BC%9A%E9%9D%92%E5%85%89%E7%9C%BC%E5%AD%A6%E7%BB%84.%20%E4%B8%AD%E5%9B%BD%E7%9C%BC%E7%A7%91%E6%89%8B%E6%9C%AF%E5%90%8E%E6%84%9F%E6%9F%93%E6%80%A7%E7%9C%BC%E5%86%85%0A%E7%82%8E%E8%AF%8A%E7%96%97%E4%B8%93%E5%AE%B6%E5%85%B1%E8%AF%86%20(2022%20%E5%B9%B4)%5BJ%5D.%20%E4%B8%AD%E5%8D%8E%E7%9C%BC%E7%A7%91%E6%9D%82%E5%BF%97%2C%202022%2C%2058(7)%3A%20487-%0A499.%20DOI%3A10.3760%2Fcma.j.cn112142-20220301-00088.%3Cbr%3E%0AChinese%20Vitreo%E2%80%91%20Retina%20Society%20of%20Chinese%20Medical%20Association%2C%0AChinese%20Cataract%20and%20Refractive%20SurgerySociety%2C%20China%20Ocular%0ATrauma%20Society%2C%20Glaucoma%20Group%20of%20Ophthalmology%20Branch%20of%0AChinese%20Medical%20Association.%20Chinese%20expert%20consensus%20on%20the%0Adiagnosis%20and%20management%20of%20infectious%20endophthalmitis%20after%0Aophthalmic%20surgery.%20Chin%20J%20Ophihalmol%2C%202022%2C%2058(7)%3A%20487-499.%0ADOI%3A%2010.3760%2Fcma.j.cn112142-20220301-00088.Chinese%20Vitreo%E2%80%91%20Retina%20Society%20of%20Chinese%20Medical%20Association%2C%0AChinese%20Cataract%20and%20Refractive%20SurgerySociety%2C%20China%20Ocular%0ATrauma%20Society%2C%20Glaucoma%20Group%20of%20Ophthalmology%20Branch%20of%0AChinese%20Medical%20Association.%20Chinese%20expert%20consensus%20on%20the%0Adiagnosis%20and%20management%20of%20infectious%20endophthalmitis%20after%0Aophthalmic%20surgery.%20Chin%20J%20Ophihalmol%2C%202022%2C%2058(7)%3A%20487-499.%0ADOI%3A%2010.3760%2Fcma.j.cn112142-20220301-00088.
12、Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1%
voriconazole in humans[J]. Arch Ophthalmol, 2008, 126(1): 18-
22. DOI: 10.1001/archophthalmol.2007.8.Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1%
voriconazole in humans[J]. Arch Ophthalmol, 2008, 126(1): 18-
22. DOI: 10.1001/archophthalmol.2007.8.
13、Al-Mezaine HS, Al-Assiri A, Al-Rajhi AA. Incidence, clinical
features, causative organisms, and visual outcomes of delayedonset pseudophakic endophthalmitis[J]. Eur J Ophthalmol, 2009,
19(5): 804-811. DOI: 10.1177/112067210901900519.Al-Mezaine HS, Al-Assiri A, Al-Rajhi AA. Incidence, clinical
features, causative organisms, and visual outcomes of delayedonset pseudophakic endophthalmitis[J]. Eur J Ophthalmol, 2009,
19(5): 804-811. DOI: 10.1177/112067210901900519.
14、Shen YC, Wang CY, Tsai HY, et al. Intracameral voriconazole
injection in the treatment of fungal endophthalmitis resulting
from keratitis[J]. Am J Ophthalmol, 2010, 149(6): 916-921. DOI:
10.1016/j.ajo.2010.01.024.Shen YC, Wang CY, Tsai HY, et al. Intracameral voriconazole
injection in the treatment of fungal endophthalmitis resulting
from keratitis[J]. Am J Ophthalmol, 2010, 149(6): 916-921. DOI:
10.1016/j.ajo.2010.01.024.
15、Kalaiselvi G, Narayana S, Krishnan T, et al. Intrastromal
voriconazole for deep recalcitrant fungal keratitis: a case series[J].
Br J Ophthalmol, 2015, 99(2): 195-198. DOI: 10.1136/
bjophthalmol-2014-305412.Kalaiselvi G, Narayana S, Krishnan T, et al. Intrastromal
voriconazole for deep recalcitrant fungal keratitis: a case series[J].
Br J Ophthalmol, 2015, 99(2): 195-198. DOI: 10.1136/
bjophthalmol-2014-305412.
16、Hegazy HM, Kivilcim M, Peyman GA, et al. Evaluation of toxicity
of intravitreal ceftazidime, vancomycin, and ganciclovir in a
silicone oil-filled eye[J]. Retina, 1999, 19(6): 553-557. DOI: 10.
1097/00006982-199911000-00013.Hegazy HM, Kivilcim M, Peyman GA, et al. Evaluation of toxicity
of intravitreal ceftazidime, vancomycin, and ganciclovir in a
silicone oil-filled eye[J]. Retina, 1999, 19(6): 553-557. DOI: 10.
1097/00006982-199911000-00013.
17、Holland GN. AIDS and ophthalmology: the first quarter
century[J]. Am J Ophthalmol, 2008, 145(3): 397-408. e1.
DOI:10.1016/j.ajo.2007.12.001.Holland GN. AIDS and ophthalmology: the first quarter
century[J]. Am J Ophthalmol, 2008, 145(3): 397-408. e1.
DOI:10.1016/j.ajo.2007.12.001.
18、Neoh CF, Leung L, Chan E, et al. Open-label study of absorption
and clearance of 1% voriconazole eye drops[J]. Antimicrob Agents
Chemother, 2016, 60(11): 6896-6898. DOI: 10.1128/AAC.00683-
16.Neoh CF, Leung L, Chan E, et al. Open-label study of absorption
and clearance of 1% voriconazole eye drops[J]. Antimicrob Agents
Chemother, 2016, 60(11): 6896-6898. DOI: 10.1128/AAC.00683-
16.
19、Senthilkumari S, Lalitha P, Prajna NV, et al. Single and multidose
ocular kinetics and stability analysis of extemporaneous
formulation of topical voriconazole in humans[J]. Curr Eye Res,
2010, 35(11): 953-960. DOI: 10.3109/02713683.2010.506968.Senthilkumari S, Lalitha P, Prajna NV, et al. Single and multidose
ocular kinetics and stability analysis of extemporaneous
formulation of topical voriconazole in humans[J]. Curr Eye Res,
2010, 35(11): 953-960. DOI: 10.3109/02713683.2010.506968.
20、中华医学会眼科学分会眼外伤学组. 中国外伤性感染性眼内
炎防治专家共识 (2023 年)[J]. 中华眼科杂志, 2023, 59(2): 90-95.
DOI: 10.3760/cma.j.cn112142-20221018-00521.
China Ocular Trauma Society. Chinese expert consensus on the
prophylaxis and management of traumatic infectious
endophthalmitis (2023)[J]. Chin J Ophihalmol, 2023, 59(2): 90-95.
DOI: 10.3760/cma.j.cn112142-20221018-00521.China Ocular Trauma Society. Chinese expert consensus on the
prophylaxis and management of traumatic infectious
endophthalmitis (2023)[J]. Chin J Ophihalmol, 2023, 59(2): 90-95.
DOI: 10.3760/cma.j.cn112142-20221018-00521.
21、Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice
guidelines for the diagnosis and management of aspergillosis:
2016 update by the infectious diseases society of America[J]. Clin
Infect Dis, 2016, 63(4): e1-e60. DOI: 10.1093/cid/ciw326.Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice
guidelines for the diagnosis and management of aspergillosis:
2016 update by the infectious diseases society of America[J]. Clin
Infect Dis, 2016, 63(4): e1-e60. DOI: 10.1093/cid/ciw326.
22、Rhee%20MK%2C%20Ahmad%20S%2C%20Amescua%20G%2C%20et%20al.%20Bacterial%20keratitis%20preferred%0Apractice%20pattern%C2%AE%5BJ%5D.%20Ophthalmology%2C%202024%2C%20131(4)%3A%20P87-P133.%0ADOI%3A%2010.1016%2Fj.ophtha.2023.12.035.Rhee%20MK%2C%20Ahmad%20S%2C%20Amescua%20G%2C%20et%20al.%20Bacterial%20keratitis%20preferred%0Apractice%20pattern%C2%AE%5BJ%5D.%20Ophthalmology%2C%202024%2C%20131(4)%3A%20P87-P133.%0ADOI%3A%2010.1016%2Fj.ophtha.2023.12.035.
